Trial Profile

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Casdozokitug (Primary) ; Toripalimab (Primary)
Indications Liver cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Coherus Biosciences

12 May 2025 According to a Coherus BioSciences media release, first data readout from this study is expected in 1H 2026.
22 Jan 2025 Results demonstrating durability of response and improvement in depth of response were presented in the Coherus BioSciences media release.
22 Jan 2025 According to a Coherus BioSciences media release, company announced the final data from this study and, These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium taking place January 23-25, 2025, in San Francisco, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com